CN1793156A - Luteolin-7-O-bata-glucuronide and its extracting process and application thereof - Google Patents
Luteolin-7-O-bata-glucuronide and its extracting process and application thereof Download PDFInfo
- Publication number
- CN1793156A CN1793156A CN 200510082836 CN200510082836A CN1793156A CN 1793156 A CN1793156 A CN 1793156A CN 200510082836 CN200510082836 CN 200510082836 CN 200510082836 A CN200510082836 A CN 200510082836A CN 1793156 A CN1793156 A CN 1793156A
- Authority
- CN
- China
- Prior art keywords
- luteolin
- glucuronide
- solution
- reference substance
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a new compound sweet reseda element-7-0-beta-D-glucuronide that has the function of curing cardiovascular diseases, improving microcirculation and reducing blood fat. The invention also relates to the use of the new compound in several fields.
Description
Technical field
The present invention relates to a kind of new compound, specifically, is luteolin-7-O-β-D-glucuronide, the invention still further relates to the preparation and the purposes of this compound.
Background technology
Herba Ixeritis Sonchifoliae is commonly called as Herba Ixeritis Sonchifoliae, and the dry aerial parts for feverfew Herba Ixeritis Sonchifoliae [Ixerissonchifolia (Bge.) Hance] life in 2 years mainly are distributed in ground such as northeast, Inner Mongol.Has effect clearing heat and detoxicating, swelling and pain relieving.Through research for many years, now be developed to traditional Chinese medicine injection [KUDIEZI ZHUSHEYE], at the clinical cardiovascular and cerebrovascular diseases that is widely used in, obtained good curative effect.Now therefrom isolate compounds such as multiple flavonoid, lactone, adenosine class.It is reported that its adenosine-adenosine that contains has and expands the hat effect, be one of effective constituent of KUDIEZI ZHUSHEYE.But we find that at work the content of adenosine in KUDIEZI ZHUSHEYE is very low, only are 0.0025mg/ml, in addition, wherein still contain a large amount of flavones ingredients.General flavone content reaches more than the 0.4mg/ml in this injection liquid, is 160 times of adenosine content.Now report, multiple flavonoid compound has the hat of expansion, increases myocardial consumption of oxygen, effects such as microcirculation improvement, and for this reason, we have carried out following work, with the effective constituent of conclusive evidence KUDIEZI ZHUSHEYE.Found that a kind of new compound luteolin-7-O-β-D-glucuronide, its pharmacological research does not appear in the newspapers as yet, thereby has finished the present invention.
Summary of the invention
One of purpose of the present invention provides a kind of new compound.
Another purpose of the present invention provides the preparation method of this compound.
Another purpose of the present invention provides the purposes of this compound at the medicine of preparation treatment cardiovascular disorder, especially acute myocardial ischemia.
Another object of the present invention provides the purposes of this compound in measuring Herba Ixeritis Sonchifoliae active constituent content method.
Another purpose of the present invention provides the purposes of this compound in measuring KUDIEZI ZHUSHEYE active constituent content method.
New compound of the present invention is luteolin-7-O-β-D-glucuronide, is yellow powder.Structural formula is:
The extraction and separation method of compound of the present invention is:
With Herba Ixeritis Sonchifoliae is the dry aerial parts of feverfew Herba Ixeritis Sonchifoliae [Ixeris sonchifolis (Bge.) Hance] life in 2 years, twice of boiling, 1 hour for the first time, 0.5 hour for the second time, merge decoction liquor, be concentrated into every 1ml and be equivalent to crude drug in whole 0.5g, put and be chilled to below 40 ℃, under agitation add 10% calcium hydroxide breast and regulate pH value to 10, placed 12 hours, centrifugal, centrifugal sediment is weighed, be suspended in 5.3 times of amount 95% ethanol (make contain alcohol amount reach 80%), add 50% sulphuric acid soln and regulate pH value to 3～4, fully stirring makes and reacts completely, centrifugal, supernatant liquor adds in 40% sodium hydroxide solution and pH value to 7.0, filters filtrate recycling ethanol, and wave most ethanol, add 0.5 times of amount vinyl acetic monomer degreasing twice, water liquid is with 0.5 times of saturated n-butanol extraction of water gaging three times, merging n-butanol extracting liquid, reclaim under reduced pressure is to doing, obtain the crude flavonoid powder extract, silica gel on the dry method (thin-layer chromatography silica gel H) post is with chloroform-methanol-acetic acid (70: 35: 10) wash-out, use the monitoring of TLC method, intercept the 4th component, handle, use C through methyl alcohol
18Semipreparative column (250 * 10mm, 5 μ) is a moving phase with acetonitrile-1% glacial acetic acid solution (17: 83), carries out HPLC and separates preparation, gets yellow unformed powder.Analyze through HPLC, prove that purity is all more than 95%.
This powder dissolves in methyl alcohol, is soluble in the methanol-water mixed solvent, and hydrochloric acid-magnesium powder reaction and Molish reaction all are positive, and prompt for flavonoid glycoside compound.
Thin-layer chromatography is checked: it is an amount of to get above-mentioned yellow amorphous powder, adds methyl alcohol and makes the solution that every 1ml contains 0.5mg.As need testing solution.Test according to tlc (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw above-mentioned need testing solution 5 μ l, point is developping agent in the silica gel H precoated plate with chloroform-methanol-acetic acid (70: 35: 10), launches, spray is with 10% aluminum chloride ethanolic soln, 105 ℃ were heated several minutes, and put under the ultra-violet lamp (365nm) and inspect, in the trial-product chromatogram, should be single yellow fluorescence spot, show that this product is the simplification compound.
The structure authentication method:
1, instrument and material
Fusing point test YB-1 type drug melting point determinator; Infrared spectra is changed spectrophotometer with Tianjin, island FTIR-8400 type fourier infrared; Ultra-violet absorption spectrum Tianjin, island UV-2550 ultraviolet spectrophotometer; Mass spectrum is measured with IonSpec HiResESI type mass spectrograph, adopts positive ion to detect; Nucleus magnetic resonance BrukerAV600 type nmr determination; Thin-layer chromatography and column chromatography silica gel are Haiyang Chemical Plant, Qingdao's product; Solvent and developer are analytical pure.
2, structure is identified
Compound I I (No. 2) is yellow powder, dissolves in methyl alcohol, water, and reaction of HCL-Mg powder and Molish reaction all are positive, and prompting may be flavonoid glycoside compound.
Hydrolysis: 1. get sample 1mg No. 2, be mixed with the solution of 2mg/ml, draw 4 μ l, point sample is placed in the lidded container on efficient thin layer plate, adds hydrochloric acid 5ml, airtight after, put 60 ℃ of water-bath 1.5hr, take out and wave most hydrochloric acid, standby.Get sample No. 2, luteolin reference substance solution (2mg/ml), apigenin reference substance solution (2mg/ml) is put respectively on same efficient thin layer plate, launches.Developping agent is: chloroform-methanol-water (26: 12: 4) takes off a layer 9ml behind the shake well in separating funnel, adds the Glacial acetic acid of 1ml.After the hydrolysis,, after No. 2 sample hydrolysis,, the spot of same color is arranged as a result, show that the glucoside unit of No. 2 samples is luteolin in the position identical with luteolin with the colour developing of 10% aluminum chloride ethanolic soln.
2. get sample 5mg No. 2, add the trifluoroacetic acid 1ml of 2mol/L, airtight, put hydrolysis 1.5hr in 121 ℃ of baking ovens.After the hydrolysis, with N
2Air-flow dries up, and adds methyl alcohol 2ml, dries up, and repeats 5 times, places 85 ℃ of dry 3hr of baking oven, is put in the exsiccator and spends the night.Add ammoniacal liquor 1ml, NaBH
415mg, room temperature is placed 1.5hr, jolting frequently.Drip Glacial acetic acid and do not produce, with N to there being bubble
2Dry up, add 10% acetate methanol solution 2ml, dry up, repeat 5 times, add pyridine 0.5ml, after the aceticanhydride 1ml dissolving, sealing and in 121 ℃ of heating 3hr is cooled to room temperature.N
2Dry up, add methyl alcohol 1ml, dry up, repeat 5 times, add entry 3ml dissolving back with CHCl
3Extract three times, merge CHCl
3Layer dries up, and adds several acetone solutions, carries out gas chromatography (condition slightly), and with the contrast of standard sugar alcohol acetylate, the part that proves its sugar is glucose or glucuronic acid.
Ultraviolet spectral analysis: the ultraviolet spectrogram of No. 2 samples is seen Fig. 1.
Show respectively in maximum absorption band at 205nm, 256nm, 266nm (shoulder), 348nm place,, confirm that further its aglycon is a luteolin with the uv-spectrogram basically identical of luteolin.
High resolution mass spectrum: the high resolution mass spectrum of No. 2 samples is seen Fig. 2.
High resolution mass spectrum provides, and the M+1 peak of this compound is 463.08515, and molecular formula should be C by retrieval
21H
18O
12, identical with the glucuronic acid glycosides molecular formula of luteolin.
The H-NMR spectrum is seen Fig. 3.
H-NMR (DMSO-d
6, 600MH
2) show: 7.42 (1H, H-2), 7.39 (1H, H-6 '), 6.48 (1H, H-5 ') constitute B ring ABX coupled system proton; 6.76 6.70,6.40 is flavones parent nucleus 8.3.6 position proton signal; 5.08 be the anomeric proton signal of sugar.
13C-NMR; No. 2 samples
13The C-NMR spectrum is seen Fig. 4.
13C-NMR (DMSO-d
6) show 21 carbon, wherein 99.54 is that two carbon signals are overlapping, and the DEPT spectrum has confirmed this point (see figure 5), and signal and ownership that these are sugared see Table 1.(the data basically identical of Luteolin7-O-β-D-glucuronide), COSY spectrum (Fig. 6) has further confirmed its structure with the luteolin 7-O-β-D glucuronide of bibliographical information.
Differentiate that through UV, IR, MS, NMR spectrum and hydrolysis, TLC, GC proof is respectively galuteolin and luteolin-7-O-β-D-glucuronide.
Luteolin-7-o-β-D-glucuronide check clone can be separated from KUDIEZI ZHUSHEYE, and purity can reach more than 98%.Luteolin-7-o-β-D-glucuronide content in KUDIEZI ZHUSHEYE is higher relatively, is quantitative quality control index so select it, adopts its content of high effective liquid chromatography for measuring, and method is easy, favorable reproducibility, and highly sensitive, specificity is strong.Concrete grammar is as follows:
1, instrument and reagent
Agilent 1100 Series high performance liquid chromatographs; Acetonitrile is a chromatographically pure, and phosphoric acid is chromatographically pure, and other reagent are analytical pure.
Luteolin-7-o-β-D-glucuronide reference substance (lot number 040520, purity 98.60% are provided by the institute for drug control, Jilin Province).
2, the chromatographic condition octadecylsilane chemically bonded silica is a weighting agent; Acetonitrile-0.4% phosphoric acid solution (18: 82) is a moving phase; The detection wavelength is 348nm; Flow velocity: 0.9ml/min; 40 ℃ of column temperatures.Number of theoretical plate calculates by luteolin-7-o-β-D-glucuronide peak should be not less than 3000.
3, the preparation of reference substance solution and need testing solution
3.1 it is an amount of that the preparation precision of reference substance solution takes by weighing luteolin-7-o-β-D-glucuronide reference substance, adds water and make the solution that every 1ml contains 0.5mg, promptly.(ultrasonic in case of necessity 5 minutes).
3.2 this product is got in the preparation of need testing solution, as need testing solution.
4, methodological study
4.1, the investigation of chromatographic condition
The selection of chromatographic column: once selected Diamonsil-C for use
18(5 μ, 4.6 * 250mm), Kromasil-C
18(5 μ, 4.6 * 250mm), Luna C
18(luteolin-7-o-β-D-glucuronide all can reach baseline separation for 5 μ, 4.6 * 250mm) three kinds of chromatographic columns, imitates the highest with the 3rd root chromatogram column post.
Detect the selection of wavelength: get luteolin-7-o-β-D-glucuronide reference substance solution and in 200～400nm wavelength region, carry out UV scanning.Luteolin-7-o-β-D-glucuronide has maximum absorption at 210nm, 255nm, 348nm wavelength place as a result, and with under 348nm, impurity peaks is few in the trial-product chromatogram.Therefore selected detection wavelength is 348nm.
The selection of moving phase:,, select acid solution in the moving phase for use for preventing the chromatographic peak hangover according to the character and the separating behavior on the octadecylsilane chemically bonded silica chromatographic column thereof of flavones ingredient.Once tested four kinds of flow phase system: 1. 2. acetonitrile-0.4% phosphoric acid solution of acetonitrile-0.4% phosphoric acid solution (18: 82), 10～31% acetonitrile gradient wash-outs are 4. methyl alcohol-1% glacial acetic acid solution (30: 70) of acetonitrile-1% glacial acetic acid solution (20: 80) 3., the result shows, with 1. 2. middle flow phase system good separating effect, wherein, 1. to plant moving phase lower to the instrument requirement, and suitability is wider, therefore, adopting acetonitrile-0.4% phosphoric acid solution (18: 82) is the moving phase of this method.
4.2, that the preparation precision of typical curve takes by weighing luteolin-7-o-β-D-glucuronide reference substance is an amount of, with water dissolution and quantitatively dilution make the solution that every 1ml contains 0.1972mg.The above-mentioned solution 1,3,5,7,9,13,15 of accurate absorption, 20ul inject liquid chromatograph, measure, with sample size (μ g) to peak area drawing standard curve, its regression equation is y=-3.2748+2075.45C (γ=0.99999). the result shows, under above-mentioned chromatographic condition, luteolin-7-o-β-D-glucuronide sample size is in 0.1972～3.944 μ g scope, and peak area and concentration are good linear relationship, meet the requirement of external standard method quantitative assay, the results are shown in following table 1.
Table 1
| Sampling volume (ul) | 1 | 3 | 5 | 7 | 9 | 13 | 15 | 20 |
| Sample size (ug) integrated value | 0.1972 406.6 | 0.5916 1220.8 | 0.9860 2064.2 | 1.3804 2852.7 | 1.7748 3671.0 | 2.5636 5311.9 | 2.958 6134.4 | 3.944 8189.5 |
4.3, blank test is the reasonableness of further investigating experimental design, make by former prescription technology not contain Herba Ixeritis Sonchifoliae negative control sample.Measure the record color atlas by the sample determination method.The result shows, in that the peak occurs with luteolin-7-o-β-the corresponding retention time of D-glucuronide reference substance place is noiseless, thereby proof this law is rationally feasible.
4.4, stability test is accurate draws same lot number sample solution 5 μ l, by above-mentioned chromatographic condition, respectively at 0,2,7,12,22 hour sample introduction 1 time, the results are shown in following table 2.
Table 2 stability test result
| Time (hour) | 0 | 2 | 7 | 12 | 22 |
| Peak area integrated value average RSD% | 1445.60 | 1446.75 | 1445.70 1448.50 0.26 | 1449.77 | 1454.67 |
The result shows that in 22 hours, the content of luteolin in the need testing solution-7-o-β-D-glucuronide is basicly stable.
4.5 same lot number sample is got in the circulation ratio test, presses the operation of text method, independent mensuration five times the results are shown in following table.Show that this method circulation ratio is good.
Table 3 reproducible test results
| NO | Measured value (mg/ml) | Mean value (mg/ml) | RSD％ |
| 1 2 3 4 5 | 0.1390 0.1388 0.139l 0.1389 0.1383 | 0.13882 | 0.224 |
4.6, precision test is accurate draws same lot number sample solution 5 μ l, by above-mentioned chromatographic condition, repeat sample introduction 5 times, measure peak area value and be respectively 1445.59839,1447.43665,1444.11670,1445.71313,1446.75452, A=1445.92, RSD=0.087%.The result shows, the good accuracy of used instrument tool.
4.7, recovery test gets 5 parts in the sample of known content, every part of 5ml, put in the 10ml measuring bottle, the accurate luteolin-7-o-β-D-glucuronide reference substance solution that adds is diluted with water to scale, shake up, that is, make need testing solution, measure with method, calculate recovery rate the results are shown in following table.
Table 4 average recovery measurement result
| Test number | Sampling amount (ml) | Known quantity in the sample (mg) | Add-on (mg) | The amount of recording (mg) | The rate of recovery (%) |
| 1 2 3 4 5 | 5 5 5 5 5 | 0.6941 0.6941 0.6941 0.6941 0.6941 | 0.649 0.649 0.649 0.649 0.649 | 1.341 1.344 1.344 1.340 1.345 | 99.68 100.1 100.1 99.52 100.3 |
| Average recovery rate=99.94% RSD=0.33% | |||||
As above shown in the table, recording luteolin-7-o-β-D-glucuronide average recovery rate is 99.94% RSD=0.33%, and the result shows that this law rate of recovery is better, and accuracy is higher.
5, sample determination result and content limit are determined to measure 22 batch samples that two manufacturing enterprises produce in accordance with the law, press the operation of text method, under above-mentioned chromatographic condition, use external standard method, the results are shown in following table 5.
Table 5 samples contg measurement result
| Manufacturing enterprise | Lot number | Luteolin-7-o-β-D-glucuronide content (mg/ml) |
| Tonghua China medicine company | 030711 | 0.2381 |
| Tonghua China medicine company | 030819 | 0.2478 |
| Tonghua China medicine company | 030822 | 0.2315 |
| Tonghua China medicine company | 030825 | 0.2518 |
| Tonghua China medicine company | 030831 | 0.2398 |
| Tonghua China medicine company | 040101 | 0.1447 |
| Tonghua China medicine company | 040104 | 0.1413 |
| Tonghua China medicine company | 040105 | 0.1406 |
| Tonghua China medicine company | 040107 | 0.1411 |
| Tonghua China medicine company | 040106 | 0.1402 |
According to above-mentioned sample determination result, and with reference to the Herba Ixeritis Sonchifoliae medicinal material measurement result and the rate of transform (is 60% calculating by the rate of transform) thereof, the tentative every 1ml of this product contains Herba Ixeritis Sonchifoliae with luteolin-7-o-β-D-glucuronide (C
21H
17O
12) meter, must not be less than 0.080mg.
Compound of the present invention can also be used for the Quality Control measuring method of this medicinal material as the quantitative quality control index of medicinal material Herba Ixeritis Sonchifoliae.Concrete measuring method is as follows:
Measuring method is measured according to high performance liquid chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 D).
Chromatographic condition and system suitability test are weighting agent with octadecylsilane chemically bonded silica; Acetonitrile-0.4% phosphoric acid solution (18: 82) is a moving phase; The detection wavelength is 348nm; 40 ℃ of column temperatures.Number of theoretical plate calculates by luteolin-7-o-β-D-glucuronide peak should be not less than 3000.
It is an amount of that the preparation precision of reference substance solution takes by weighing luteolin-7-o-β-D-glucuronide reference substance, adds water and make the solution that every 1ml contains 0.5mg, promptly.(ultrasonic in case of necessity 5 minutes).
The preparation of need testing solution divides different sites to take out 20g from every batch of medicinal material, and cataclasm, mixing is got 5g, and accurate the title decides, and adds water 100ml, boils 1.5 hours, filters, and filtrate concentrates and is settled in the 50ml measuring bottle, shakes up, and filters with 0.45 μ m filter membrane, promptly.
Accurate respectively reference substance solution and each the 5 μ l of need testing solution of drawing of assay method inject liquid chromatograph, measure, promptly.
This product contains luteolin-7-o-β-D-glucuronide (C
21H
17O
12) must not be lower than 0.13%.
Measure the medicinal material in the different places of production according to the method described above, measurement result is as follows:
Table 6 medicinal material measurement result
| The place of production | Luteolin-7-o-β-D-glucuronic acid content (%) |
| Haicheng City 030601 | 0.131 |
| Haicheng City 030602 | 0.130 |
| Haicheng City 030603 | 0.169 |
| Haicheng City 030604 | 0.0855 |
| Haicheng City 030605 | 0.141 |
| Haicheng City 030606 | 0.115 |
| Haicheng City 030607 | 0.139 |
| Haicheng City 030608 | 0.175 |
| Haicheng City 030609 | 0.166 |
| Haicheng City 030610 | 0.213 |
| Middle part in 2003 | 0.0989 |
| Bai Shanqian portion | 0.246 |
| The Bai Shan rear portion | 0.165 |
| The Bai Shan middle part | 0.221 |
| Rear portion in 2003 | 0.140 |
| Rear portion in 2002 | 0.134 |
| Front portion in 2003 | 0.152 |
| Front portion in 2002 | 0.137 |
According to above-mentioned test-results, tentative this product contains luteolin-7-o-β-D-glucuronide (C
21H
17O
12) must not be lower than 0.13%.
Compound of the present invention has effects such as treatment cardiovascular disorder, microcirculation improvement and lipopenicillinase; especially acute myocardial ischemia and acute myocardial infarction there is obvious provide protection; it can change (the T wave height is alarmmed and the ST section is raised) to the acute myocardial ischemia electrocardiogram(ECG and improve significantly; also can obviously dwindle the MIS of rats with acute myocardial infarction; reduce serum CPK and LDH activity, and can obviously reduce whole blood and plasma viscosity.
Effect experiment is as follows:
Experimental animal Wistar big white mouse, the male and female dual-purpose, body weight 180～280g, conformity certification number are: the moving word 10-5112 of doctor, supplied with by high-new medical faunae research centre, Changchun.
Test drug The compounds of this invention (0.2mg/ml): the Jilin Prov. Inst. of Chinese Medicine and Chinese Medical Science is supplied with, lot number: 20041005.Sodium chloride injection: the sincere pharmaceutcal corporation, Ltd in sky, Changchun produces lot number: 20031005.
(x ± s) expression adopts t check the carrying out statistical study of two groups of sample average comparisons to the statistical method experimental data with means standard deviation.
Method and result
1, Pituitrin is brought out the Electrocardiographic influence of rat heart muscle ischemia
1.1 method
Careful electric sieve selects 60 of qualified Wistar rats, male and female half and half, and body weight 142～157g is divided into 6 groups at random, that is: control group, positive drug group, The compounds of this invention 2.4,4.8mg/kg organize 10 every group.Abdominal injection (ip) administration respectively of each group of The compounds of this invention, positive drug group ip nifedipine 10mg/kg, control group ip sodium chloride injection, injection capacity is 2ml/kg, every day 1 time, continuous 3 days.30min after the last administration, each group is all from sublingual vein injection of pituitrin (Shanghai Hefeng Pharmaceutical Co., Ltd.'s product, dilute with physiological saline during test) lu/kg, in 10 seconds, inject and finish, trace 5 minutes electrocardiogram(ECG, measure to give ST section in the Pituitrin 30 seconds, the T ripple changes and 1,2,3,4,5 minute changes in heart rate.
The result
Behind the control group sublingual vein injection of pituitrin, visible rat ST section and T ripple are all obviously raised, and show that Pituitrin can bring out the Acute Myocardial Ischemia in Rats ECG change.The The compounds of this invention group improves significantly (p＜0.05) to the Acute Myocardial Ischemia in Rats electrocardiogram(ECG variation that the intravenous injection Pituitrin brings out, but action intensity is not as nifedipine.Each dosage group of The compounds of this invention can be brought out the rat decreased heart rate to Pituitrin is not then had obvious influence, sees Table 7,8.
Table 7 The compounds of this invention to Pituitrin bring out the Electrocardiographic influence of Acute Myocardial Ischemia in Rats (x ± s, n=10)
| Group | Dosage (mg/kg) | The T ripple changes (mv) | The ST section changes (mv) | ||
| Before the medicine | The value of raising | Before the medicine | The value of raising | ||
| Control group The compounds of this invention nifedipine | - 2.4 4.8 10 | 0.203±0.116 0.233±0.057 0.250±0.054 0.226±0.053 | 0.108±0.092 -0.056±0.085 ** -0.050±0.052 ** -0.099±0.079 *** | 0.041±0.081 0.034±0.074 0.050±0.079 0.034±0.072 | 0.088±0.072 0.011±0.061 * 0.010±0.074 * 0.001±0.081 ** |
Compare * p＜0.05, * * p＜0.01 with control group
Table 8 The compounds of this invention to Pituitrin bring out the Acute Myocardial Ischemia in Rats heart rate influence (x ± s, n=10)
| Group | Before the medicine (inferior/min) | Different time changes percentage (%) behind the medicine | ||||
| 1min | 2min | 3min | 4min | 5min | ||
| Control group-The compounds of this invention 2.4mg/kg 4.8mg/kg nifedipine 10mg/kg | 309±52 309±71 298±77 308±67 | -24.3±13.5 -19.0±23.9 -30.8±26.3 -11.3±11.4 * | -27.9±16.0 -26.0±14.8 -19.4±15.9 -13.5±9.11 * | -27.1±12.4 -24.8±10.8 -24.6±12.0 -14.7±9.23 * | -24.4±14.7 -23.4±12.1 -26.6±9.29 -17.6±10.0 | -26.5±13.7 -23.8±12.3 -25.1±10.5 -20.3±9.93 |
Compare * p＜0.05 with control group
2, to the provide protection of rat acute myocardial infarction
2.1 method
105 of Wistar rats, the male and female dual-purpose, body weight 242～266g is divided into 7 groups at random, that is: sham operated rats, infarct model group, positive drug group and The compounds of this invention 2.4,4.8mg/kg organize 15 every group.The ip administration respectively of each group of The compounds of this invention, sham operated rats and infarct model group ip sodium chloride injection, positive drug group ip nifedipine 10mg/kg, injection capacity is 2ml/kg, every day 1 time, continuous 5 days.Measure the rat normal ECG after the last administration during 30min, press literature method making myocardial infarction model
[1]Under etherization, rat is faced upward the position, be fixed on the operating table, 3～4 intercostals are opened chest from the left side, expose heart, in between pulmonary conus and left atrium, find out the coronary artery left anterior descending branch, with No. 0 line ligation immediately it, send heart back to thoracic cavity, and extrude thoracic cavity inner blood and gas, close the thoracic cavity rapidly, wholely open the chest time and be no more than 30 seconds, not ligation of sham operated rats and only put surgical thread.Treat the ligation coronary artery after 24 hours,, measure rat II lead electrocardiogram with vetanarcol 30mg/kg i.p anesthesia.Then, abdominal aortic cannulation is got blood, surveys serum aspartic acid aminotransferase (AST), creatine phosphokinase (CPK) and serum lactic dehydrogenase (LDH) activity.With 3500 revolutions per seconds of centrifugal bloods of LDZ5-2 whizzer, get blood plasma, measure plasma viscosity, and survey whole blood lowly cut, in cut, height cuts viscosity.Take out rat heart rapidly,, remove atrium and fatty tissue, weigh with physiological saline flush away chambers of the heart inner blood.With 4～5 of ventricle crosscuts, put in chlorination nitro blue tetrazolium (NB-T) phosphoric acid buffer, take out the back fully in 37 ℃ of water bath with thermostatic control dyeing.Healthy tissues dyeing, ischemic tissue does not dye.Downcut ischemic tissue and weigh, with the percentage calculation myocardial infarct size (MIS) of ischemic myocardium and ventricle weight in wet base.
2.2 result
2.2.1 to rats with acute myocardial infarction MIS and serum AST, CPK, the active influence of LDH
Compare with sham operated rats, infarct model group MIS and AST, serum CPK, LDH activity all obviously increase (p＜0.05～0.001), and prompting rat acute myocardial infarction model is set up successfully.Compare with the infarct model group, The compounds of this invention two dosage all can obviously dwindle MIS (p＜0.05 or p＜0.01), obviously reduce serum CPK, AST and LDH activity (p＜0.05 or p＜0.01), see Table 9.
Table 9 The compounds of this invention to rats with acute myocardial infarction MIS and serum AST, CPK, the active influence of LDH (x ± s, n=10)
| Group | MIS (％) | AST (u/L) | CPK (u/L) | LDH (u/L) |
| Sham-operation Zu Infarction Model Zu The compounds of this invention 2.4mg/kg 4.8mg/kg nifedipine 10mg/kg | 1.41±1.2 *** 33.7±6.6 24.5±6.6 ** 21.6±4.8 ** 13.9±5.8 *** | 737.92±110.78 * 1069.4±325.45 821.96±233.26 796.16±137.72 * 787.17±150.48 * | 663.79±184.58 ** 1226.8±567.92 743.07±207.46 * 731.44±150.42 * 682.36±142.05 ** | 1575.55±569.56 ** 2601.33±629.08 1956.42±717.43 * 1936.41±377.80 * 1737.07±580.70 ** |
Compare * p＜0.05, * * p＜0.01, * * * p＜0.001 with the infarct model group
2.2.2 influence to rats with acute myocardial infarction whole blood and plasma viscosity
With sham operated rats relatively, infarct control group whole blood is low to be cut, in cut, Gao Qie and plasma viscosity all obviously increase (p＜0.05～0.01), increasing with blood viscosity during prompting rat acute myocardial infarction.Compare with the infarct model group, The compounds of this invention two dosage can obviously reduce whole blood low cut, in cut, Gao Qie and plasma viscosity (p＜0.05～0.01), its effect is suitable with nifedipine, sees Table 10.
Table 10 The compounds of this invention to the influence of rats with acute myocardial infarction whole blood and plasma viscosity (x ± s, n=10)
| Group | Dosage (mg/kg) | Whole blood viscosity | Plasma viscosity (120/s) | ||
| 10/s | 60/s | 150/s | |||
| Sham operated rats infarct model group The compounds of this invention nifedipine | - - 2.4 4.8 10 | 12.30±3.03** 19.78±5.37 15.08±3.68 * 14.91±3.87 * 15.38±3.21 * | 5.30±1.81* 7.38±2.06 5.46±1.06 * 5.43±0.86 * 5.85±1.11 | 4.50±0.78** 5.99±1.37 4.67±0.54 * 4.58±0.51 ** 4.72±0.44 * | 1.70±0.33** 2.44±0.68 1.74±0.28 ** 1.76±0.59 * 1.8l±0.30 * |
Compare * p＜0.05, * * p＜0.01 with the infarct model group
Description of drawings
Fig. 1 invention compound UV spectrogram;
Fig. 2 invention compound high resolution mass spectrum;
Fig. 3 invention compound H-NMR spectrogram;
Fig. 4 invention compound
13The C-NMR spectrogram;
Fig. 5 invention Compound D EPT spectrogram;
Fig. 6 invention Compound C OSY spectrogram.
Claims (9)
1. luteolin-7-O-β-D-glucuronide, structural formula is:
2. the extracting method of luteolin-7-O-β-D-glucuronide, it is characterized in that twice of Herba Ixeritis Sonchifoliae medicinal material boiling, 1 hour for the first time, 0.5 hour for the second time, merge decoction liquor, be concentrated into every 1ml and be equivalent to crude drug in whole 0.5g, put and be chilled to below 40 ℃, under agitation add 10% calcium hydroxide breast and regulate pH value to 10, placed 12 hours, centrifugal, centrifugal sediment is weighed, be suspended in 5.3 times of amount 95% ethanol, make to contain alcohol amount and reach 80%, add 50% sulphuric acid soln and regulate pH value to 3～4, fully stir to make and react completely, centrifugal, supernatant liquor adds in 40% sodium hydroxide solution and pH value to 7.0, filters, filtrate recycling ethanol, and wave most ethanol, and adding 0.5 times of amount vinyl acetic monomer degreasing twice, water liquid is with 0.5 times of saturated n-butanol extraction of water gaging three times, merge n-butanol extracting liquid, reclaim under reduced pressure obtains the crude flavonoid powder extract, silicagel column on the dry method to doing, with 70: 35: 10 chloroform-methanols-acetum wash-out, use the monitoring of TLC method, intercept the 4th component, handle through methyl alcohol, use 250 * 10mm semipreparative column, with 17: 83 acetonitriles-1% glacial acetic acid solution is moving phase, carries out HPLC and separates preparation, gets yellow unformed powder.
3. luteolin-7-O-β-D-glucuronide is in the purposes of preparation treatment cardiovascular disorder, microcirculation improvement, blood lipid-lowering medicine.
4. purposes according to claim 3, wherein said cardiovascular disorder are acute myocardial ischemia or acute myocardial infarction.
5. the purposes of luteolin-7-O-β-D-glucuronide in measuring the Herba Ixeritis Sonchifoliae quality controlling means.
6. purposes according to claim 5, wherein measuring Herba Ixeritis Sonchifoliae has
Method is
A) it is an amount of that the preparation precision of reference substance solution takes by weighing luteolin-7-o-β-D-glucuronide reference substance, adds water and make the solution that every 1ml contains 0.5mg, promptly; Ultrasonic in case of necessity 5 minutes;
B) preparation of need testing solution divides different sites to take out 20g from every batch of medicinal material, and cataclasm, mixing is got 5g, and accurate the title decides, and adds water 100ml, boils 1.5 hours, filters, and filtrate concentrates and is settled in the 50ml measuring bottle, shakes up, and filters with 0.45 μ m filter membrane, promptly;
C) test of chromatographic condition and system suitability is a weighting agent with octadecylsilane chemically bonded silica; Acetonitrile-0.4% phosphoric acid solution (18: 82) is a moving phase; The detection wavelength is 348nm; 40 ℃ of column temperatures.Number of theoretical plate calculates by luteolin-7-o-β-D-glucuronide peak should be not less than 3000;
D) accurate respectively reference substance solution and each the 5 μ l of need testing solution of drawing of assay method inject liquid chromatograph, measure, promptly;
This product contains luteolin-7-o-β-D-glucuronide (C
21H
17O
12) must not be lower than 0.13%.
7. the purposes of luteolin-7-O-β-D-glucuronide in measuring the control of the Herba Ixeritis Sonchifoliae quality of the pharmaceutical preparations.
8. purposes according to claim 7, wherein said Herba Ixeritis Sonchifoliae preparation is KUDIEZI ZHUSHEYE or lyophilized injectable powder.
9. according to claim 7 or 8 described purposes, wherein said mensuration Herba Ixeritis Sonchifoliae quality of the pharmaceutical preparations control method is
A) it is an amount of that the preparation precision of reference substance solution takes by weighing luteolin-7-o-β-D-glucuronide reference substance, adds water and make the solution that every 1ml contains 0.5mg, promptly; Ultrasonic in case of necessity 5 minutes;
B) this product is got in the preparation of need testing solution, as need testing solution;
C) the chromatographic condition octadecylsilane chemically bonded silica is a weighting agent; Acetonitrile-0.4% phosphoric acid solution (18: 82) is a moving phase; The detection wavelength is 348nm; Flow velocity: 0.9ml/min; 40 ℃ of column temperatures.Number of theoretical plate calculates by luteolin-7-o-β-D-glucuronide peak should be not less than 3000;
D) accurate respectively reference substance solution and each the 5 μ l of need testing solution of drawing of assay method inject liquid chromatograph, measure, promptly;
The every 1ml of this product contains Herba Ixeritis Sonchifoliae with luteolin-7-o-β-D-glucuronide (C
21H
17O
12) meter, must not be less than 0.080mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100828361A CN1332971C (en) | 2004-07-26 | 2005-07-11 | Luteolin-7-O-bata-glucuronide and its extracting process and application thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200410070625 | 2004-07-26 | ||
| CN200410070625.1 | 2004-07-26 | ||
| CNB2005100828361A CN1332971C (en) | 2004-07-26 | 2005-07-11 | Luteolin-7-O-bata-glucuronide and its extracting process and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1793156A true CN1793156A (en) | 2006-06-28 |
| CN1332971C CN1332971C (en) | 2007-08-22 |
Family
ID=36804815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100828361A Active CN1332971C (en) | 2004-07-26 | 2005-07-11 | Luteolin-7-O-bata-glucuronide and its extracting process and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1332971C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102512433A (en) * | 2011-11-09 | 2012-06-27 | 沈阳双鼎科技有限公司 | Application of digitoflavone-7-O-beta-D-glucuronide in fundus disease treatment |
| CN104277083A (en) * | 2013-07-04 | 2015-01-14 | 河北以岭医药研究院有限公司 | Preparation method and application of luteolin-7-O-beta-D-glucuronide |
| CN105769896B (en) * | 2016-03-01 | 2019-04-30 | 上海中医药大学附属岳阳中西医结合医院 | Application of the luteolin -7- glucosulfone aldehydic acid glycosides in the drug of preparation myocardial damage or fibrosis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1419912A (en) * | 2001-11-17 | 2003-05-28 | 郑秋生 | Cyanidenon, apigenin -7-0-beta-D-glucoside use and related medicine |
-
2005
- 2005-07-11 CN CNB2005100828361A patent/CN1332971C/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102512433A (en) * | 2011-11-09 | 2012-06-27 | 沈阳双鼎科技有限公司 | Application of digitoflavone-7-O-beta-D-glucuronide in fundus disease treatment |
| CN104277083A (en) * | 2013-07-04 | 2015-01-14 | 河北以岭医药研究院有限公司 | Preparation method and application of luteolin-7-O-beta-D-glucuronide |
| CN104277083B (en) * | 2013-07-04 | 2019-04-23 | 河北以岭医药研究院有限公司 | A kind of luteolin -7-o- β-D-Glucose aldehydic acid glycosides Preparation method and use |
| CN105769896B (en) * | 2016-03-01 | 2019-04-30 | 上海中医药大学附属岳阳中西医结合医院 | Application of the luteolin -7- glucosulfone aldehydic acid glycosides in the drug of preparation myocardial damage or fibrosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1332971C (en) | 2007-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ye et al. | Immunomodulatory sesquiterpene glycosides from Dendrobium nobile | |
| CN101810659A (en) | Total saponins of salvia chinensis benth, and medical application and preparation method thereof | |
| CN101637567A (en) | Rhizoma ligustici wallichii quality control method in Chinese medicine preparation | |
| CN102445514A (en) | Detection method of traditional Chinese medicine preparation jinshuibao capsule | |
| CN1332971C (en) | Luteolin-7-O-bata-glucuronide and its extracting process and application thereof | |
| CN100387243C (en) | Quality control method of ixeris sonchifolia injection | |
| CN1895296A (en) | Inspection for lucid ganoderma product oral preparation quality | |
| CN108451959A (en) | The application of galloyl glucose glycoside derivative and the pharmaceutical composition for treating hyperuricemia | |
| CN1243025C (en) | Germanium enriced gold needle mushroom polysaccharide and its making metehod and use | |
| CN1216896C (en) | Echinocystic acid preparation, medicinal preparation and new use as medicine | |
| CN103823016B (en) | Detecting method of DanTianJingShu oral preparation | |
| CN106749492B (en) | A kind of steroid saponin compound and its preparation method and application | |
| CN101670041A (en) | Method for controlling quality of astragalus in Chinese medicine preparation | |
| CN1188406C (en) | Cattail pollen extract and preparation process and use thereof | |
| CN102304160B (en) | Preparation method and application of luteolin-7-O-gentibioside | |
| CN108498526A (en) | A kind of pharmaceutical composition and the preparation method and application thereof of prevention blahs aypnia disease | |
| CN101239093A (en) | Active component in albizia julibrissin with inhibiting angiogenesis function and preparation method and application thereof | |
| CN103454373B (en) | Method for detecting medicament for treating dysmenorrhea | |
| CN103083388A (en) | Preparation method of fructus gleditsiae total saponins | |
| CN114436884A (en) | Burdock ceramide compound and preparation method and application thereof | |
| CN101637566A (en) | Salvia miltiorrhiza quality control method in Chinese medicine preparation | |
| CN1253467C (en) | Process for preparing periplocin | |
| CN1935199A (en) | Quality control method for Chinese medicine compound preparation | |
| CN1057300C (en) | Glucoside compound of catechine and preparation method and use thereof | |
| CN110907545B (en) | Method for simultaneously determining contents of six metabolites in small gold preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Tonghua Huaxia Pharmaceutical Co., Ltd. Assignor: Hua Yuqiang Contract fulfillment period: 2009.12.16 to 2025.7.10 contract change Contract record no.: 2009220000084 Denomination of invention: Luteolin -7-O- beta -D- glucuronide and its extraction method and use Granted publication date: 20070822 License type: Exclusive license Record date: 20091224 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.12.16 TO 2025.7.10; CHANGE OF CONTRACT Name of requester: TONGHUA HUAXIA PHARMACEUTICAL CO., LTD Effective date: 20091224 |